MedTrace Logo

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

NCT00667901 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2009-12-11

No results posted yet for this study

Summary

RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma.

PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

riluzole

GENETIC

protein expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

GENETIC

western blotting

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

neoadjuvant therapy

PROCEDURE

therapeutic conventional surgery

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Medicine and Dentistry of New Jersey

    lead OTHER

Principal Investigators

  • James S. Goydos, MD · Rutgers Cancer Institute of New Jersey

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-10-31
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00667901 on ClinicalTrials.gov